Noxopharm Ltd has released a press release.
Noxopharm August 2019 Corporate Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Noxopharm
- NOX Announces AU$26 Million Funding Facility
- Conference Hears of Positive Interim Data from LuPIN Trial
- Promising Data Leads to Expansion of LuPIN Trial
- LuPIN Trial Demonstrates High Rates of Response
- DARRT Treatment Has Lasting Disease Control at Six Months
Later from Noxopharm
- Pre-Clinical Evidence Confirms Veyonda Abscopal Effect
- NOX Receives FY19 Federal Government R&D Tax Rebate
- More Evidence that Veyonda Enhances RT in Prostate Cancer
- Appendix 4E and Audited Financial Statements FY19
- Veyonda and Radiotherapy Profiled at Key Oncology Meeting
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm